

Edgar Filing: NUTRA PHARMA CORP - Form NT 10-Q

NUTRA PHARMA CORP
Form NT 10-Q
August 16, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

COMMISSION FILE NUMBER 000-32141
CUSIP 67060U 10 9

(Check One): ☐ Form 10-KSB ☐ Form 11-K ☒ Form 10-QSB ☐ Form N-SAR
For Period Ended: JUNE 30, 2004

☐ Transition Report on Form 10-K
☐ Transition Report on Form 20-F
☐ Transition Report on Form 11-K
☐ Transition Report on Form 10-Q
☐ Transition Report on Form N-SAR

For the Transition Period Ended: _____

Read attached instruction sheet before preparing form. Please print or type.
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify
the item(s) to which the notification relates: _____

PART I -- REGISTRANT INFORMATION

NUTRA PHARMA CORP.

Full name of registrant

Not applicable

Former name if applicable

1829 Corporate Drive

Address of principal executive office (Street and number)

Boynton Beach, Florida 33426

City, state and zip code

PART II -- RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), (Paragraph 23, 047),
the following should be completed. (Check box if appropriate.)

☒ (a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
☒ (b) The subject annual report, semi-annual report, transition report on
Form 10-K, 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or
before the 15th calendar day following the prescribed due date; or the subject
quarterly report or transition report on Form 10-Q, or portion thereof will be
filed on or before the fifth calendar day following the prescribed due date; and
(Amended in Release No. 34-26589 (Paragraph 72, 435), effective April 12, 1989,
54 F.R. 10306.)

Edgar Filing: NUTRA PHARMA CORP - Form NT 10-Q

[] | (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III -- NARRATIVE

State below in reasonable detail why the Form 10-K, 11-K, 20-F 10-Q, N-SAR or the transition report portion thereof could not be filed within the prescribed time period. (Amended in Release No. 34-26589 (Paragraph 72, 435), effective April 12, 1989, 54 F.R. 10306.)

We were not able to complete the required Financial Information for the period ended June 30, 2004 on a timely basis.

PART IV -- OTHER INFORMATION

- (1) Name and telephone number of person to contact in regard to this notification

Rik J. Deitsch

(954)

509-0911

(Name)

(Area Code) (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). [X] Yes [] No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? [] Yes [X] No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Nutra Pharma Corp.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 16, 2004

/s/ Rik J. Deitsch

President/Chief Executive Officer/Chief Financial Officer